Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH)—previously known as nonalcoholic ...

The drug, an apoptosis signal-regulating kinase 1 (ASK1) inhibitor, did not meet the primary endpoint of a ≥ 1-stage histologic improvement in fibrosis without worsening of NASH in the STELLAR-4 ...

including that 4% of patients who received its drug at either dose had a two- or three-stage improvement in fibrosis with no worsening NASH, which was not seen in any patient in the placebo group.

The liver is essential for digestion, metabolism, detoxification, and fluid regulation. While alcohol abuse is a known cause ...

Investigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic ...

Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...

In conclusion, pentoxifylline leads to a significant reduction in the AST and ALT levels in patients with NASH. This improvement ... inflammation and fibrosis stage. Randomized controlled trials ...

Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a positive outlook on MDGL stock.

Several studies have reported changes in hepatic histology from liver biopsies obtained at the time of bariatric surgery and after weight loss ( Table 1). Previous reviews [19,75–77] have ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...